[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

UY29070A1 - Enantiómeros de heterocíclicos fusionados y sus usos - Google Patents

Enantiómeros de heterocíclicos fusionados y sus usos

Info

Publication number
UY29070A1
UY29070A1 UY29070A UY29070A UY29070A1 UY 29070 A1 UY29070 A1 UY 29070A1 UY 29070 A UY29070 A UY 29070A UY 29070 A UY29070 A UY 29070A UY 29070 A1 UY29070 A1 UY 29070A1
Authority
UY
Uruguay
Prior art keywords
fusioned
enantiomers
heterocyclic
heterocyclic enantiomers
new compounds
Prior art date
Application number
UY29070A
Other languages
English (en)
Inventor
Block Michael Howard
Aquila Brian
Davies Audrey
Ezhuthachan Jayachandran
Pontz Timothy
Russell Daniel John
Theoclitou Marie-Elena
Zheng Xiaolan
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37904998&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UY29070(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of UY29070A1 publication Critical patent/UY29070A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La presente invención se relaciona con nuevos compuestos que contienen la fórmula estructural (I) y con sus composiciones farmacéuticas y sus métodos de uso. Estos nuevos compuestos proporcionan un tratamiento o profilaxis para el cáncer.
UY29070A 2004-08-18 2005-08-16 Enantiómeros de heterocíclicos fusionados y sus usos UY29070A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US60236604P 2004-08-18 2004-08-18

Publications (1)

Publication Number Publication Date
UY29070A1 true UY29070A1 (es) 2006-03-31

Family

ID=37904998

Family Applications (1)

Application Number Title Priority Date Filing Date
UY29070A UY29070A1 (es) 2004-08-18 2005-08-16 Enantiómeros de heterocíclicos fusionados y sus usos

Country Status (18)

Country Link
US (3) US20080293744A1 (es)
EP (1) EP1781674A1 (es)
JP (1) JP2008509977A (es)
KR (1) KR20070046176A (es)
CN (1) CN101027309B (es)
AU (1) AU2005273705B8 (es)
BR (1) BRPI0514390A (es)
CA (1) CA2575188A1 (es)
IL (1) IL180810A0 (es)
MX (1) MX2007001953A (es)
MY (1) MY141233A (es)
NO (1) NO20071005L (es)
RU (1) RU2447077C2 (es)
SA (1) SA05260258B1 (es)
TW (1) TW200616977A (es)
UA (1) UA89201C2 (es)
UY (1) UY29070A1 (es)
ZA (1) ZA200701082B (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101952292A (zh) * 2007-11-13 2011-01-19 艾科斯有限公司 人磷脂酰肌醇3-激酶δ的抑制剂
MX2011013816A (es) 2009-06-29 2012-04-11 Incyte Corp Pirimidinonas como inhibidores de pi3k.
DK2751109T3 (en) 2011-09-02 2017-01-23 Incyte Holdings Corp HETEROCYCLYLAMINES AS PI3K INHIBITORS
US8940742B2 (en) 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
NZ718430A (en) 2013-10-04 2021-12-24 Infinity Pharmaceuticals Inc Heterocyclic compounds and uses thereof
US9751888B2 (en) 2013-10-04 2017-09-05 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
CN113620958A (zh) 2014-03-19 2021-11-09 无限药品股份有限公司 用于治疗PI3K-γ介导的障碍的杂环化合物
WO2015191677A1 (en) 2014-06-11 2015-12-17 Incyte Corporation Bicyclic heteroarylaminoalkyl phenyl derivatives as pi3k inhibitors
US9708348B2 (en) 2014-10-03 2017-07-18 Infinity Pharmaceuticals, Inc. Trisubstituted bicyclic heterocyclic compounds with kinase activities and uses thereof
RS63963B1 (sr) 2015-02-27 2023-03-31 Incyte Holdings Corp Postupak pripreme pi3k inhibitora
CA2998469A1 (en) 2015-09-14 2017-03-23 Infinity Pharmaceuticals, Inc. Solid forms of isoquinolinones, and process of making, composition comprising, and methods of using the same
US10759806B2 (en) 2016-03-17 2020-09-01 Infinity Pharmaceuticals, Inc. Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as PI3K kinase inhibitors
US10919914B2 (en) 2016-06-08 2021-02-16 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
WO2024103067A1 (en) * 2022-11-10 2024-05-16 Ribometrix, Inc. COMPOUNDS AND COMPOSITIONS AS eIF4E INHIBITORS AND USES THEREOF

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5792767A (en) 1995-01-27 1998-08-11 Abbott Laboratories Bicyclic substituted hexahydrobenz e! isoindole alpha-1 adrenergic antagonists
KR100482919B1 (ko) 1996-03-11 2005-10-12 신젠타 파티서페이션즈 아게 살충제로서의피리미딘-4-온유도체
SI1140941T1 (en) 1998-12-23 2005-04-30 Bristol-Myers Squibb Pharma Company Nitrogen containing heterobicycles as factor xa inhibitors
ATE286033T1 (de) 1999-09-16 2005-01-15 Curis Inc Vermittler von igel signalwegen, deren zusammenstellungen und verwendungen
ES2263501T3 (es) 1999-10-27 2006-12-16 Cytokinetics, Inc. Procedimiento y composiciones que utilizan quinazolinonas.
US7230000B1 (en) * 1999-10-27 2007-06-12 Cytokinetics, Incorporated Methods and compositions utilizing quinazolinones
US6545004B1 (en) 1999-10-27 2003-04-08 Cytokinetics, Inc. Methods and compositions utilizing quinazolinones
EA007538B1 (ru) 2000-12-11 2006-10-27 Туларик Инк. Антагонисты cxcr3
US6900214B2 (en) 2001-03-29 2005-05-31 Bristol-Myers Squibb Company Cyano-substituted dihydropyrimidine compounds and their use to treat diseases
US20020165240A1 (en) 2001-03-29 2002-11-07 Kimball Spencer David Method of treating proliferative diseases using Eg5 inhibitors
US6809102B2 (en) * 2001-03-29 2004-10-26 Bristol-Myers Squibb Company Cyano-substituted dihydropyrimidine compounds and their use to treat diseases
US20030096813A1 (en) 2001-04-20 2003-05-22 Jingrong Cao Compositions useful as inhibitors of GSK-3
CA2465491A1 (en) 2001-11-07 2003-05-15 Merck & Co., Inc. Mitotic kinesin inhibitors
WO2003043995A1 (en) * 2001-11-20 2003-05-30 Cytokinetics, Inc. Process for the racemization of chiral quinazolinones
WO2003050064A2 (en) 2001-12-06 2003-06-19 Merck & Co., Inc. Mitotic kinesin inhibitors
EP1458726B1 (en) * 2001-12-06 2009-07-15 Merck & Co., Inc. Mitotic kinesin inhibitors
AU2002357043B2 (en) * 2001-12-06 2008-04-24 Merck Sharp & Dohme Corp. Mitotic kinesin inhibitors
EP1481077B1 (en) * 2001-12-06 2009-11-04 Merck & Co., Inc. Mitotic kinesin inhibitors
US7244723B2 (en) * 2001-12-06 2007-07-17 Merck & Co., Inc. Substituted furopyrimidinones as a mitotic kinesin inhibitors
EP1480980A4 (en) 2002-02-15 2005-04-20 Cytokinetics Inc SYNTHESIS OF QUINAZOLINONES
RU2308454C9 (ru) 2002-04-17 2008-05-10 Цитокинетикс, Инк. Соединения, композиции на их основе и способы их использования
CN100491358C (zh) 2002-05-09 2009-05-27 赛特凯恩蒂克公司 嘧啶酮类化合物、组合物及方法
AU2003270015A1 (en) * 2002-05-09 2003-12-02 Cytokinetics, Inc. Compounds, compositions, and methods
TW200407143A (en) 2002-05-21 2004-05-16 Bristol Myers Squibb Co Pyrrolotriazinone compounds and their use to treat diseases
JP2006506401A (ja) 2002-05-23 2006-02-23 メルク　エンド　カムパニー　インコーポレーテッド 有糸分裂キネシン阻害薬
CA2483627A1 (en) 2002-05-23 2003-12-04 Merck & Co., Inc. Mitotic kinesin inhibitors
AU2003265242A1 (en) * 2002-05-23 2003-12-22 Cytokinetics, Inc. Compounds, compositions, and methods
CA2489367A1 (en) 2002-06-14 2003-12-24 Cytokinetics, Inc. Compounds, compositions, and methods
WO2004006865A2 (en) 2002-07-17 2004-01-22 Cytokinetics, Inc. Compounds, compositions, and methods
EP1537089A4 (en) 2002-07-23 2008-04-16 Cytokinetics Inc CONNECTIONS, COMPOSITIONS AND PROCEDURES
AU2003262747A1 (en) 2002-08-21 2004-03-11 Cytokinetics, Inc. Compounds, compositions, and methods
WO2004024086A2 (en) 2002-09-13 2004-03-25 Cytokinetics, Inc. Compounds, compositions and methods
WO2004034972A2 (en) 2002-09-30 2004-04-29 Cytokinetics, Inc. Compounds, compositions, and methods
US7476743B2 (en) 2002-10-11 2009-01-13 Cytokinetics, Inc. Compounds, compositions, and methods
EP1558589A4 (en) 2002-10-11 2008-01-09 Cytokinetics Inc COMPOUNDS, COMPOSITIONS AND METHODS
EP1594849A4 (en) 2003-01-17 2007-07-04 Cytokinetics Inc COMPOUNDS, COMPOSITIONS, AND METHODS
ES2326647T3 (es) * 2003-03-07 2009-10-16 Astrazeneca Ab Heterociclos condensados y sus usos.
AR050920A1 (es) 2003-03-07 2006-12-06 Astrazeneca Ab Enantiomeros de heterociclos fusionados seleccionados y usos de los mismos
EP1622883A4 (en) 2003-04-10 2008-04-02 Cytokinetics Inc COMPOUNDS, COMPOSITIONS AND METHODS
WO2004100873A2 (en) 2003-05-07 2004-11-25 Cytokinetics, Inc. Compounds, compositions, and methods
US20070066591A1 (en) 2003-05-14 2007-03-22 Xiangping Qian Compounds, compositions, and methods
JP2007500746A (ja) 2003-05-15 2007-01-18 サイトキネティクス・インコーポレーテッド 化合物、組成物および方法
US7022850B2 (en) * 2003-05-22 2006-04-04 Bristol-Myers Squibb Co. Bicyclicpyrimidones and their use to treat diseases
US7345046B2 (en) * 2003-05-30 2008-03-18 Chiron Corporation Heteroaryl-fused pyrimidinyl compounds as anticancer agents
CA2528771A1 (en) 2003-06-20 2004-12-29 Chiron Corporation Pyridino[1,2-a]pyrimidin-4-one compounds as anticancer agents
WO2005042697A2 (en) 2003-10-06 2005-05-12 Cytokinetics, Inc. Compounds, compositions and methods
WO2005046588A2 (en) 2003-11-07 2005-05-26 Cytokinetics, Inc. Compounds, compositions, and methods
US20050158320A1 (en) * 2003-11-12 2005-07-21 Nichols M. J. Combinations for the treatment of proliferative diseases
CA2546932A1 (en) 2003-11-25 2005-06-09 Chiron Corporation Quinazolinone compounds as anticancer agents
US7439254B2 (en) 2003-12-08 2008-10-21 Cytokinetics, Inc. Compounds, compositions, and methods
US7501416B2 (en) * 2004-02-06 2009-03-10 Bristol-Myers Squibb Company Quinoxaline compounds and methods of using them
DE602005012069D1 (de) 2004-04-06 2009-02-12 Novartis Vaccines & Diagnostic Inhibitoren von mitotischem kinesin
AU2005245492A1 (en) 2004-05-21 2005-12-01 Novartis Vaccines And Diagnostics, Inc. Substituted quinoline derivatives as mitotic kinesin inhibitors
US7576221B2 (en) 2004-06-18 2009-08-18 Novartis Vaccines And Diagnostics, Inc. Substituted imidazole derivatives
KR20070046175A (ko) 2004-08-18 2007-05-02 아스트라제네카 아베 선택된 융합 복소환 및 이의 용도
US20060041128A1 (en) 2004-08-18 2006-02-23 Astrazeneca Ab Selected fused heterocyclics and uses thereof
CA2584979A1 (en) * 2004-10-19 2006-05-11 Novartis Vaccines And Diagnostics, Inc. Indole and benzimidazole derivatives

Also Published As

Publication number Publication date
NO20071005L (no) 2007-05-16
CA2575188A1 (en) 2006-02-23
CN101027309B (zh) 2010-10-27
RU2447077C2 (ru) 2012-04-10
US20060041129A1 (en) 2006-02-23
US7498333B2 (en) 2009-03-03
UA89201C2 (ru) 2010-01-11
AU2005273705B2 (en) 2009-12-10
IL180810A0 (en) 2007-06-03
CN101027309A (zh) 2007-08-29
ZA200701082B (en) 2008-07-30
MY141233A (en) 2010-03-31
KR20070046176A (ko) 2007-05-02
RU2007109866A (ru) 2008-09-27
BRPI0514390A (pt) 2008-06-10
TW200616977A (en) 2006-06-01
AU2005273705A1 (en) 2006-02-23
AU2005273705B8 (en) 2010-01-28
EP1781674A1 (en) 2007-05-09
JP2008509977A (ja) 2008-04-03
US20090099210A1 (en) 2009-04-16
SA05260258B1 (ar) 2009-12-22
MX2007001953A (es) 2007-05-09
US20080293744A1 (en) 2008-11-27

Similar Documents

Publication Publication Date Title
UY29530A1 (es) Compuestos quimicos
UY28708A1 (es) Heterociclos sustituídos y usos de los mismos
UY29886A1 (es) Derivados de pirazol novedosos, composiciones farmaccuticas que los contienen, procedimientos para la preparacinn de los mismos y aplicaciones
UY29360A1 (es) Nuevos derivados de pirazol, composiciones farmacéuticas que los contienen, procedimientos de preparación y aplicaciones.
DK1853602T3 (da) Kemiske forbindelser
DK1853588T3 (da) Kemiske forbindelser
SV2011003903A (es) Aminotetrahidropiranos como inhibidores de dipeptidil peptidasa iv para el tratamiento o prevencion de diabetes
SV2008003045A (es) Aminotetrahidropiranos como inhibidores de dipertidil, peptidasa-iv para el tratamiento o prevencion de diabetes
GT200600199A (es) Diarilsulfonas sulfonamidas y su uso
NI201200184A (es) Morfolinopirimidinas y su uso en terapia
CL2004000917A1 (es) Compuestos derivados de tiazol; procedimiento de preparacion; composicion farmaceutica; y su uso para el tratamiento de enfermedades mediadas por 3-cinasa de dosfatidilnositol tal como enfermedades respiratorias, alergias, artritis reumatoide, osteoa
UY31065A1 (es) Heterociclos ciclicos
UY31048A1 (es) Nuevos compuestos de pirimidina y usos de los mismos
UY30025A1 (es) Derivados sustituidos de las 2-amino-5,6-dihidro pirimidin-4(3h)-onas y sus sales farmacéuticamente aceptables, composiciones farmacéuticas conteniéndolos y aplicaciones.
UY29919A1 (es) Derivados sustituidos de 3,4-dihidroisoquinolin-1-amino-trifluoroacetato, sus composiciones farmacéuticas y aplicaciones
DOP2006000169A (es) Inhibidores espiropiperidina de beta-secretasa para el tratamiento de la enfermedad de alzheimer
UY30748A1 (es) Compuesto0s novedosos
ECSP088638A (es) Bencensulfonil-cromano, tiocromano, tetrahidronaftaleno e inhibidores de gamma secretasa relacionados
UY31084A1 (es) Compuestos de azaindol para la inhibicion de b-secretasa
ECSP078062A (es) Heterociclos de 1,4-dihidropiridina-condensados, procesos para preparar los mismos, uso y composiciones que los contienen
CR10479A (es) Modulares bencimidazolicos de vr1
DOP2006000061A (es) Derivados de pirimidina para el tratamiento de trastornos hiperproliferativos
UY29818A1 (es) Nuevos compuestos de azetidina, composiciones farmaceuticas que los contienen, procesos de preparacion y sus usos terapeuticos
SV2004001555A (es) Difenilazetidinonas cationicamente sustituidas, procesos para su preparacion, medicamentos que contienen estos compuestos y sus usos
UY29070A1 (es) Enantiómeros de heterocíclicos fusionados y sus usos